X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.
Lead Product(s): Edetate Calcium Disodium,Citric Acid
Therapeutic Area: Podiatry Product Name: Revye
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.
Lead Product(s): EDTA acid,Citric Acid
Therapeutic Area: Podiatry Product Name: coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: ProgenaCare Global
Deal Size: Undisclosed Upfront Cash: $0.5 million
Deal Type: Agreement April 20, 2023
Details:
The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Salud Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023
Details:
The funding supplements the clinical development of Kane’s DispersinB Hydrogel to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds. The DispersinB is a hydrogel wound dressing containing the enzyme DispersinB and the gelling agent Pluronic® F-127.
Lead Product(s): DispersinB
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: DispersinB Hydrogel
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 04, 2022
Details:
The funding will be used primarily for product development including DispersinB and general working capital. The Company has a portfolio of biotechnologies, intellectual property (81 patents) and products developed by the Company's own biofilm research expertise.
Lead Product(s): DispersinB
Therapeutic Area: Dermatology Product Name: DispersinB
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Marc Edwards
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 06, 2022
Details:
DispersinB® wound gel underwent an extensive pre-clinical testing regimen showing it to be safe, non-toxic and non-irritating, in addition, DispersinB® significantly accelerated healing of both infected and non-infected dermal wound compared to control.
Lead Product(s): DispersinB
Therapeutic Area: Dermatology Product Name: DispersinB
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
DispersinB®, has properties that bacteriophages do not have which include superior application as a preventative therapeutic, broader spectrum of activity, and a much easier regulatory (FDA) path.
Lead Product(s): DispersinB
Therapeutic Area: Infections and Infectious Diseases Product Name: DispersinB
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Maryland School of Medicine’s Institute of Human Virology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
